Jiangsu Hengrui Medicine
600276.SS
#467
Rank
HK$342.00 B
Marketcap
HK$53.61
Share price
-1.00%
Change (1 day)
3.24%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2023 (TTM): HK$0.71

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is HK$0.71. In 2022 the company made an earnings per share (EPS) of HK$0.70 a decrease over its 2021 EPS that were of HK$0.85.

EPS history for Jiangsu Hengrui Medicine from 2002 to 2023

Annual EPS

Year EPS Change
2023 (TTM)HK$0.711.14%
2022HK$0.70-17.1%
2021HK$0.85-24.44%
2020HK$1.1320.3%
2019HK$0.9425.58%
2018HK$0.7427.55%
2017HK$0.5821.64%
2016HK$0.4813.57%
2015HK$0.4239.86%
2014HK$0.3021.33%
2013HK$0.2517.7%
2012HK$0.2125.56%
2011HK$0.1726.22%
2010HK$0.1310.3%
2009HK$0.1257.92%
2008HK$0.0766511.06%
2007HK$0.0690285.81%
2006HK$0.0371487.94%
2005HK$0.0197633.97%
2004HK$0.0147529.78%
2003HK$0.0113719.78%
2002HK$0.009489